Retatrutide dosage calculator: why none can be lawful right now

Last updated 2026-07-25

What is a retatrutide dosage calculator supposed to do?

A retatrutide dosage calculator, at least the ones circulating on gray-market vendor sites and forums, is basically a reconstitution math tool. You plug in the amount of peptide in a vial (say 5mg, 10mg, or 20mg), the amount of bacteriostatic water you plan to add, and it spits out how many units to draw on an insulin syringe to hit a target dose in milligrams or micrograms. That's the entire function. It doesn't verify purity, it doesn't know if the vial actually contains what the label claims, and it can't tell you anything about safety in a person who isn't in a monitored trial. The math itself is simple and not really the problem. If you add 2 mL of bacteriostatic water to a 10mg vial, you get a concentration of 5mg/mL, or 5,000mcg/mL. A U-100 insulin syringe measures in units where 100 units equals 1 mL, so 1mg would be 20 units. That's the whole calculation. The problem isn't the arithmetic. The problem is what you're doing the arithmetic for. Because here's the part these calculators never mention: there is no legal retail retatrutide product to reconstitute. Retatrutide has no FDA approval for any indication ^[1]. It doesn't appear on the 503A Bulks List, the exact six-substance list that governs what compounding pharmacies can legally use when a drug isn't otherwise available ^[2]. So a dosage calculator that assumes you already have a vial in hand is quietly skipping the question of how you got it, and whether that vial is legal, verified, or safe.

Is retatrutide legal to buy or use in the US right now?

No. Retatrutide is an investigational drug with no FDA-approved product under any brand name. A search of Drugs@FDA, the agency's own database of approved drug products, returns nothing for the generic name retatrutide ^[1]. Under federal law, a new drug can't be introduced into interstate commerce without an approved application, full stop, that's 21 U.S.C. 355 ^[3]. There's no exception for peptides sold as "research chemicals" if they're actually being marketed and used as drugs. Compounding pharmacies are sometimes able to legally make unapproved-in-that-form versions of drugs, but only under a strict legal cascade. Section 503A requires that a bulk substance either comply with a USP or NF monograph, or if no monograph exists, be a component of an FDA-approved drug, and only if neither of those applies can it come from the 503A Bulks List ^[4]. Retatrutide fails all three: no monograph, no approved drug it's a component of, and it's simply not on that list ^[2]. On top of that, 503A separately requires the bulk substance to come from an FDA-registered manufacturing establishment with a valid certificate of analysis ^[4]. Research-use-only material from an unregistered overseas supplier fails this requirement even if you ignore everything else. For more on how this plays out for people trying to source it, see retatrutide peptide buy.

How much bac water for 10mg retatrutide calculator math (if you're just checking the arithmetic)

People search this exact phrase a lot, so let's be straight about it: this is pure dilution math, the same math you'd use for any peptide, and it says nothing about legality or safety. If a vial is labeled 10mg and you add 2 mL of bacteriostatic water, you get 5mg/mL. Add 1 mL instead, and you get 10mg/mL, twice as concentrated, so half the injection volume for the same dose. There's no universally 'correct' amount of water, it depends on what final concentration is convenient for your syringe. A common convention some people use for a 10mg vial is 2 mL of bac water, landing on 5mg/mL, which makes a 1mg dose equal to 20 units on a U-100 insulin syringe. But convention isn't verification. If the vial's actual peptide content, purity, or sterility hasn't been independently confirmed by a real lab, the entire calculation is built on a number ("10mg") that could be wrong, understated, overstated, or contaminated. A calculator can't fix that. It can only make the wrong number look precise. The honest answer to "how much bac water for a 10mg vial" is: that's not a medical question, it's an arithmetic question about a product that has no verified content, no FDA oversight, and no legal path to your door in the first place.

How much bac water for 5mg or 20mg retatrutide calculator math

Same logic, different starting numbers. For a labeled 5mg vial, adding 1 mL of bacteriostatic water gives 5mg/mL, same concentration as the 2 mL dilution of a 10mg vial above. Adding 2 mL to a 5mg vial gives 2.5mg/mL, a more dilute solution, useful if someone wants finer control at very low doses. For a labeled 20mg vial, adding 2 mL gives 10mg/mL; adding 4 mL gives 5mg/mL. Here's a simple reference table for the arithmetic alone: | Labeled vial amount | Bac water added | Resulting concentration | 1mg dose = units (U-100 syringe) |

What doses did the actual retatrutide clinical trials use?

This is the one place real numbers exist, because trial protocols are registered and published. In the phase 2 obesity trial, participants received weekly subcutaneous injections at several dose levels, and the 12mg dose group had a mean weight reduction of 24.2 percent at 48 weeks, compared with 2.1 percent in the placebo group ^[5]. That trial is registered on ClinicalTrials.gov as NCT04881760, listed under the development code LY3437943, and the record spells out each dose arm and the injection route studied ^[6]. Retatrutide is a triple agonist, meaning it acts on three receptors at once: GIP, GLP-1, and glucagon ^[5]. That's mechanically different from semaglutide, which only hits the GLP-1 receptor, and tirzepatide, which hits GIP and GLP-1 but not glucagon ^[5]. This is part of why retatrutide has generated so much interest, the added glucagon receptor activity is thought to contribute to the weight loss magnitude seen in trials, though the phase 2 data is what exists so far, not long-term real-world outcomes. Beyond obesity, retatrutide has also been studied in registered type 2 diabetes trials ^[6], and it has moved into later-phase trials with published enrollment criteria, comparators, and endpoints, including NCT05929066 ^[7] and a second independent registration, NCT05882045 ^[8]. None of these trial records are instructions for individual use. They describe a controlled research protocol, with screening, monitoring, and a specific population, run by investigators, not the dosing schedule for a person injecting from an unverified vial at home. For the difference between trial protocols and what people are actually doing outside them, see how to take retatrutide peptide and retatrutide dosage chart.

Why isn't there a legal compounding pathway for retatrutide?

The 503A Bulks List is not a general "peptides allowed" list. It's a short, specific roster of exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[2]. None of these is a peptide, and retatrutide is not among them. Getting a new substance added requires notice-and-comment rulemaking, more than a request or a popular vote ^[7]. It's worth understanding how close this process has come for other peptides, because it shows what a real pathway looks like versus what retatrutide has. FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to consider seven different peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[7]. Retatrutide wasn't among the seven, and it has never been nominated for the list at all ^[7]. Even for the substances that were discussed, a favorable advisory committee vote doesn't create a pathway by itself, the committee's recommendations are non-binding and actual rulemaking is a separate, slower process ^[7]. Separately, the 503B bulks list, which governs outsourcing facilities rather than individual compounding pharmacies, is its own list under 21 CFR 216.24, and it likewise does not include retatrutide ^[9]. So whichever door you look at, 503A or 503B, retatrutide isn't in either one right now.

Do research-use-only disclaimers make gray-market retatrutide legal?

No, and FDA has said so explicitly and recently. In a March 31, 2026 warning letter to Gram Peptides, FDA wrote that despite "research use only" or "not for human consumption" labeling, evidence from the company's website established that its products were intended to be drugs for human use, and the letter specifically named retatrutide as one of the products marketed on that site ^[10]. The legal basis for this is 21 CFR 201.128, FDA's regulation on determining intended use. It states that intended use is established by labeling claims, advertising matter, or oral or written statements made by sellers or their representatives ^[11]. In plain terms: if your website or your sales rep talks about weight loss, fat reduction, or any therapeutic benefit, the small-print disclaimer on the vial doesn't override that. FDA looks at what you're actually telling customers to determine whether something is being marketed as a drug, and a boilerplate disclaimer buried in the terms of service doesn't change that determination. This matters for anyone weighing whether a "research use only" vendor is a loophole. It isn't one. It's a labeling choice that FDA has already stated, in writing, does not defeat drug status when the surrounding marketing says otherwise ^[10].

What about importing retatrutide personally from overseas?

FDA maintains a specific policy page on personal importation of unapproved drugs, and it applies directly here ^[1]. The general position is that FDA may allow personal-use quantities of certain unapproved drugs into the country in narrow circumstances, but this is a matter of enforcement discretion, not a legal right, and it does not apply broadly to investigational peptides marketed for weight loss. Importing a drug that has never been approved for any indication, has no monograph, and isn't legally compounded in the US, is not a safe harbor just because it crosses a border. There's also a practical safety dimension separate from the legal one. A vial imported from an overseas research-chemical supplier has typically not gone through FDA-equivalent manufacturing oversight, sterility testing, or potency verification. You're relying entirely on the seller's word, the same seller whose "research use only" language FDA has already said doesn't change what the product actually is ^[10]. If it's inaccurately dosed, contaminated, or simply not what the label claims, there's no recall system, no adverse event reporting, and no clinician who can lawfully treat you as though this were a known drug reaction, because officially, you were never on the drug at all.

What are the lawful options for someone considering retatrutide today?

If you're looking into retatrutide because of headlines about the 24.2 percent weight loss figure from the phase 2 trial ^[5], it helps to know what's actually approved and prescribable right now. Semaglutide is FDA-approved and marketed as Ozempic and Wegovy; tirzepatide is approved as Mounjaro and Zepbound ^[12]. Both have published safety data from large trial programs and years of post-approval monitoring, something retatrutide simply doesn't have yet. There's also a newer option worth knowing about: orforglipron, an oral GLP-1 receptor agonist, was approved under the brand name Foundayo (NDA 220934) in six strengths ranging from 0.8mg to 17.2mg ^[13]. That gives patients who want an oral option, rather than an injectable, an FDA-approved incretin drug to discuss with a prescriber, instead of reaching for an unregulated compound because "there's nothing else." For general, evidence-based guidance on weight management that doesn't depend on any single drug's approval status, NIDDK (the National Institute of Diabetes and Digestive and Kidney Diseases) publishes federal guidance covering diet, physical activity, and the full range of approved medical treatments . That's a reasonable starting point for anyone talking to a doctor about weight loss options while retatrutide remains investigational. On this site, retatrutide side effects and retatrutide peptide cover what the trial data actually shows in more depth, which is a useful thing to read before deciding anything.

Could a real, clinically supervised retatrutide dosage calculator ever exist?

Sure, in principle, once (if) retatrutide gets FDA approval. Every approved injectable peptide drug, semaglutide and tirzepatide included, comes with a manufacturer-specified concentration, a prefilled pen or a standardized vial, and a prescribing label with exact dosing instructions verified through the approval process. At that point, a dosage calculator becomes a genuinely useful patient tool, because the inputs (vial concentration, target dose) are backed by an approved, tested product and a prescription written by a clinician who is monitoring you. We're simply not there with retatrutide yet. It remains in trials, including later-phase studies like NCT05929066 ^[7] and NCT05882045 ^[8], and no clinician in the US can lawfully prescribe it outside of one of those trials. Retatrutide Report exists to track that process, not to get ahead of it. When and if that changes, an actual dosing calculator built around an approved product label will be a genuinely different tool than the reconstitution arithmetic circulating today. Until then, the honest use of any "retatrutide dosage calculator" you find online is as a math exercise, not a medical tool. It can tell you what dilution ratio produces what concentration. It cannot tell you what's actually in the vial, whether it's safe, or whether using it is legal. Those are three separate questions, and right now, none of them have a good answer outside a clinical trial.

Frequently asked questions

Is there a legitimate retatrutide dosage calculator for weight loss?

Not in the sense of a clinically validated tool tied to an approved product. Any calculator online today is just reconstitution arithmetic (concentration and syringe units), applied to a substance with no FDA approval and no verified vial content. It can do math correctly while still being applied to an unsafe, illegal product.

How much bac water for a 10mg retatrutide vial calculator gives what concentration?

Adding 2 mL of bacteriostatic water to a labeled 10mg vial yields 5mg/mL (1mg dose = 20 units on a U-100 syringe). Adding 1 mL yields 10mg/mL (1mg dose = 10 units). This is pure dilution math and doesn't confirm the vial's actual content, purity, or legality.

How much bac water for a 5mg retatrutide vial?

Adding 1 mL of bacteriostatic water to a labeled 5mg vial gives 5mg/mL, the same concentration as a 10mg vial diluted with 2 mL. Adding 2 mL instead gives 2.5mg/mL, a more diluted solution. Again, this only reflects arithmetic, not confirmation of what's actually in an unregulated vial.

How much bac water for a 20mg retatrutide vial?

Adding 2 mL of bacteriostatic water to a labeled 20mg vial produces 10mg/mL; adding 4 mL produces 5mg/mL. These ratios follow the same math as smaller vials, just scaled up, and carry the same caveat: the labeled amount isn't independently verified.

Is retatrutide FDA-approved?

No. A query of Drugs@FDA, the FDA's own database of approved drug products, returns no approved product for the generic name retatrutide. It remains an investigational compound studied in registered clinical trials, with no approved indication as of this writing.

Can a compounding pharmacy legally make retatrutide?

No. Section 503A requires a bulk substance to meet a USP/NF monograph, or absent that, be a component of an FDA-approved drug, or absent both, appear on the 503A Bulks List. Retatrutide meets none of the three, and the Bulks List contains only six substances, none of them peptides.

Does a research-use-only label make buying retatrutide legal?

No. FDA determines drug status by intended use, based on labeling claims, advertising, and seller statements, not disclaimers. A March 2026 FDA warning letter to Gram Peptides found the company's website established therapeutic intent for its retatrutide products despite a research-use-only label.

What dose of retatrutide was used in clinical trials?

The phase 2 obesity trial (NCT04881760) tested several weekly subcutaneous doses; the 12mg arm produced a mean 24.2 percent weight reduction at 48 weeks versus 2.1 percent for placebo, per the trial published in the New England Journal of Medicine in 2023.

Why isn't retatrutide on the 503A Bulks List?

It has simply never been nominated for it. FDA's advisory committee reviewed seven different peptides for that list in July 2026 (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, epitalon); retatrutide wasn't among them, and no nomination for retatrutide exists in FDA's public bulk substances records.

Can I legally import retatrutide from another country for personal use?

FDA's personal importation policy allows limited enforcement discretion for certain unapproved drugs in narrow circumstances, but it isn't a legal right, and it doesn't create a safe or lawful pathway for an investigational peptide with no approval status, no monograph, and no verified manufacturing standard.

What FDA-approved alternatives exist to retatrutide right now?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both FDA-approved with published trial and post-approval safety data. Orforglipron, an oral GLP-1 agonist, was approved as Foundayo (NDA 220934) in six strengths from 0.8mg to 17.2mg, giving an approved oral option as well.

What's the difference between retatrutide and tirzepatide dosing mechanisms?

Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors. Tirzepatide acts on GIP and GLP-1 receptors only, without glucagon activity. Semaglutide acts on GLP-1 alone. This mechanistic difference is part of why retatrutide's phase 2 weight loss data drew significant attention.

Sources

1. Drugs@FDA, FDA-approved drug products database: A search for retatrutide returns no FDA-approved product for any indication
2. 21 CFR 216.23, eCFR current through 2026-07-08: The 503A Bulks List contains exactly six substances, none a peptide, and retatrutide is not on it
3. 21 U.S.C. 353a(b)(1)(A)(i): 503A's ingredient cascade requires a USP/NF monograph, or component of an approved drug, or Bulks List inclusion, and retatrutide meets none
4. Jastreboff AM et al., New England Journal of Medicine, 2023: Phase 2 trial results (24.2% weight loss at 12mg vs 2.1% placebo at 48 weeks) and retatrutide's triple receptor mechanism
5. ClinicalTrials.gov NCT04881760: Trial registration listing dose arms, route, and type 2 diabetes trial existence for LY3437943/retatrutide
6. Federal Register, Docket FDA-2025-N-6895, published 16 April 2026: July 2026 advisory committee meeting on seven peptides for 503A Bulks List, retatrutide not among them, and rulemaking process requirement
7. 21 U.S.C. 355: New drugs cannot enter interstate commerce without an approved application
8. ClinicalTrials.gov NCT05882045: Second independent later-phase retatrutide trial registration
9. 21 CFR 216.24: The 503B bulks list for outsourcing facilities also does not include retatrutide
10. 21 CFR 201.128: Intended use is established by labeling claims, advertising, or seller statements, not disclaimers
11. FDA, Personal Importation: FDA's policy on personal importation of unapproved drugs applies to anyone considering importing retatrutide
12. Drugs@FDA, NDA 220934 overview: Orforglipron was approved as Foundayo under NDA 220934 in six strengths from 0.8mg to 17.2mg
13. NIDDK, Weight Management: Federal guidance on evidence-based weight management as a neutral reference point